Literature DB >> 19087221

Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.

J H Foley1, M E Nesheim.   

Abstract

BACKGROUND: Previous work by others has shown that premature clot lysis occurs in plasmas deficient in components of the intrinsic pathway, due to a failure to activate thrombin activatable fibrinolysis inhibitor (TAFI). This suggests the hypothesis that bleeding in hemophilia is due not only to defective coagulation but also enhanced fibrinolysis. These studies were carried out to quantify the extent of TAFI activation over time in normal plasma (NP) and factor VIII deficient plasma (FVIII-DP) and to determine whether soluble thrombomodulin (sTM) can correct the lysis defect in FVIII-DP.
METHODS: The time courses of TAFI activation in both NP and FVIII-DP were monitored after clotting with thrombin, PCPS and Ca(2+), +/- sTM. Clotting and lysis were measured turbidometrically and TAFIa using a functional assay.
RESULTS: Premature lysis that occurs in FVIII-DP is corrected by mixing deficient plasma with 10% NP. However, this does not fully correct the defect in TAFI activation. FVIII-DP must be mixed with up to 50% NP to attain the same TAFIa potential as NP. In FVIII-DP, sTM can correct the defect in TAFIa-dependent prolongation of lysis at low tPA concentrations and partially correct this defect at high tPA concentrations.
CONCLUSIONS: TAFI activation increases as the concentration of FVIII increases. FVIII at a level of 10% fully corrects the lysis defect in spite of the extent of TAFI activation being only one half that obtained with 100% FVIII. In addition, sTM increases TAFI activation sufficiently to correct the premature lysis defect in FVIII-DP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19087221     DOI: 10.1111/j.1538-7836.2008.03261.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

2.  Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.

Authors:  Vikas Bhat; Annette von Drygalski; Andrew J Gale; John H Griffin; Laurent O Mosnier
Journal:  Thromb Haemost       Date:  2015-10-15       Impact factor: 5.249

3.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

4.  TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Authors:  Tine Wyseure; Tingyi Yang; Jenny Y Zhou; Esther J Cooke; Bettina Wanko; Merissa Olmer; Ruchi Agashe; Yosuke Morodomi; Niels Behrendt; Martin Lotz; John Morser; Annette von Drygalski; Laurent O Mosnier
Journal:  JCI Insight       Date:  2019-10-03

Review 5.  Advances and challenges in hemophilic arthropathy.

Authors:  Tine Wyseure; Laurent O Mosnier; Annette von Drygalski
Journal:  Semin Hematol       Date:  2015-10-26       Impact factor: 3.851

6.  Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.

Authors:  Tine Wyseure; Esther J Cooke; Paul J Declerck; Niels Behrendt; Joost C M Meijers; Annette von Drygalski; Laurent O Mosnier
Journal:  Blood       Date:  2018-07-19       Impact factor: 25.476

Review 7.  Bleeding related to disturbed fibrinolysis.

Authors:  Krasimir Kolev; Colin Longstaff
Journal:  Br J Haematol       Date:  2016-08-01       Impact factor: 6.998

8.  Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes.

Authors:  Natalie Mathews; Fred G Pluthero; Margaret L Rand; Ann Marie Stain; Manuel Carcao; Victor S Blanchette; Walter H A Kahr
Journal:  Res Pract Thromb Haemost       Date:  2022-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.